Novo Nordisk Announces Significant Price Cuts for Ozempic and Wegovy
Novo Nordisk has announced substantial price reductions for its weight loss and diabetes drugs, Ozempic and Wegovy. Starting January 1, 2027, the company will decrease list prices by up to 50%, making the drugs more affordable for patients. Wegovys list price will drop from $1,349 to $675 per month, and Ozempics list price will fall from $1,028 to $675 per month. These changes will primarily benefit insured patients, particularly those on high-deductible plans or with co-insurance, as many plans base coverage and out-of-pocket costs on list prices. Novo Nordisk had previously lowered prices for uninsured patients and secured a deal to make the drugs more affordable for Medicare users. The announcement comes after the company shared trial results for its upcoming weight loss drug, CagriSema, which did not perform as well as competitors like Eli Lillys Zepbound and Mounjaro.
Support the show
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN
advertise@thednn.ai
This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai
View sources & latest updates
https://sources.thednn.ai/83ce3cd62ef310fc
